High flow nasal oxygen for prevention of intubation in acute non-hypercapnic hypoxemic respiratory failure in immunocompromised patients, a randomized trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171106003

Enrollment

Registered

2017-11-06

Start date

2017-12-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute hypoxemic respiratory failure due to pneumonia in immunocompromised patients

Interventions

noninvasive ventilation (NIV) ,high&#45

flow nasal oxygen (HFNO)

Experimental Device,Experimental Device

NIV,HFNO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: all the following 1. Immunocompromised patients: solid or hematologic malignancy, received immunosuppressive drug or steroid at a dose> 20 mg/day of prednisolone for > 30 days, HIV infection 2. Require nasal low-flow oxygen of 4 L/min to maintain PaO2 above 60 mmHg or SpO2> 90% for > 1 hour 3. Age >= 18 years

Exclusion criteria

Exclusion criteria: Exclusion 1. PaCO2> 45 mmHg 2. Post-extubation respiratory failure (respiratory failure within 48 hr after extubation) 3. Life-threatening ARF requiring immediate IMV 4. Shock 5. Active pulmonary tuberculosis 6. Contraindications to NIV 7. A do-not-intubate order 8. Patients refused to participate the study

Design outcomes

Primary

Measure	Time frame
Required intubation and IMV within 48 hours of randomization within 48 hours of randomization rate of intubation	—

Secondary

Measure	Time frame
Mortality 30-day mortality rate	—

Countries

Thailand

Contacts

Public ContactJuthamas Inchai

Faculty of medicine,Chiang Mai University

juinchai@gmail.com+66 53 936396

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

High flow nasal oxygen for prevention of intubation in acute non&#45;hypercapnic hypoxemic respiratory failure in immunocompromised patients&#44; a randomized trial